Post-transcriptional regulation of adapter molecules by IL-10 inhibits TLR-mediated activation of antigen-presenting cells

Leukemia

Volumn 23, Issue 3, 2009, Pages 535-544

  Knodler A ^a   Schmidt, S M ^a   Bringmann, A ^b   Weck, M M ^a   Brauer, K M ^a   Holderried, T A W ^b   Heine, A K ^b   Grunebach F ^a   Brossart, P ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CHEMOKINE RECEPTOR CCR7; CYTOKINE; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR 2; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHATIDYLINOSITOL 3 KINASE; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVATION; CELL FUNCTION; CELL MATURATION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 62549118666     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.301     Document Type: Article

References (54)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
2. Kawai T, Akira S. TLR signaling. Cell Death Differ 2006; 13: 816-825.
3. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002; 2: 725-734.
4. Foletta VC, Segal DH, Cohen DR. Transcriptional regulation in the immune system: All roads lead to AP-1. J Leukoc Biol 1998; 63: 139-152.
5. Fernandez-Botran R, Sanders VM, Mosmann TR, Vitetta ES. Lymphokine-mediated regulation of the proliferative response of clones of T helper 1 and T helper 2 cells. J Exp Med 1988; 168: 543-558.
6. Allavena P, Piemonti L, Longoni D, Bernasconi S, Stoppacciaro A, Ruco L et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 1998; 28: 359-369.
7. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997; 159 4772-4760.
8. Brossart P, Zobywalski A, Grünebach F, Behnke L, Stuhler G, Reichardt VL et al. Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells. Cancer Res 2000; 60: 4485-4492.
9. Allavena P, Piemonti L, Longoni D, Bernasconi S, Stoppacciaro A, Ruco L et al. IL-10 prevents the generation of dendritic cells from CD14+ blood monocytes, promotes the differentiation to mature macrophages and stimulates endocytosis of FITC-dextran. Adv Exp Med Biol 1997; 417: 323-327.
10. Enk AH, Angeloni VL, Udey MC, Katz SI. Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J Immunol 1993; 151: 2390-2398.
11. Steinbrink K, Jonuleit H, Müller G, Schuler G, Knop J, Enk AH. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 1999; 93: 1634-1642.
12. Wirths S, Reichert J, Grünebach F, Brossart P. Activated CD8+ T lymphocytes induce differentiation of monocytes to dendritic cells and restore the stimulatory capacity of interleukin 10-treated antigen-presenting cells. Cancer Res 2002; 62: 5065-5068.
13. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995; 270: 9558-9563.
14. Bhattacharyya S, Sen P, Wallet M, Long B, Baldwin Jr AS, Tisch R. Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the P13K/Akt pathway and of IkappaB kinase activity. Blood 2004; 104: 1100-1109.
15. Riley JK, Takeda K, Akira S, Schreiber RD, Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. J Biol Chem 1999; 274: 16513-16521.
16. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005; 37: 19-24.
17. Rommel C, Clarke BA, Zimmermann S, Nunez L, Rossman R, Reid K et al Differentiation stage-specific inhibition ofthe Raf-MEK-ERK pathway by Akt. Science 1999; 286: 1738-1741.
18. Brossart P, Grünebach F, Stuhler G, Reichardt VL, Mohle R, Kanz L et al. Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor. Blood 1998; 92: 4238-4247.
19. Bringmann A, Schmidt SM, Weck MM, Brauer KM, von Schwarzenberg K, Werth D et al. Zolodponic acid inhibits the function of Toll-like receptor 4 ligand activated monocyte-derived dendritic cells. Leukemia 2007; 21: 732-738.
20. Nencioni A, Lauber K, Grünebach F, Van Parijs L, Denzlinger C, Wesselborg S et al. Cyclopentenone prostaglandins induce lymphocyte apoptosis by activating the mitochondrial apoptosis pathway independent of external death receptor signaling. J Immunol 2003; 171: 5148-5156.
21. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194: 863-869.
22. Schag K, Schmidt SM, Müller MR, Weinschenk T, Appel S, Weck MM et al. Identification of C-met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes. Clin Cancer Res 2004, 10: 3658-3666.
23. Boss CN, Grünebach F, Brauer K, Hantschel M, Mirakaj V, Weinschenk T et al. Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen. Clin Cancer Res 2007; 13: 3347-3355.
24. Gunn MD. Chemokine mediated control of dendritic cell migration and function. Semin Immunol 2003; 15: 271-276.
25. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 1998; 2: 253-258.
26. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-260.
27. Ouaaz F, Arron J, Zheng Y, Choi Y, Beg AA. Dendritic cell development and survival require distinct NF-kappaB subunits. Immunity 2002; 16: 257-270.
28. Baldwin Jr AS. The NF-kappa B and I kappa B proteins: New discoveries and insights. Annu Rev Immunol 1996; 14: 649-683.
29. Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, Hiscott J. Triggering the interferon antiviral response through an IKK-related pathway. Science 2003; 300: 1148-1151.
30. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 2003; 4: 491-496.
31. Tsujimura H, Tamura T, Kong HJ, Nishiyama A, Ishii KJ, Klinman DM et al. Toll-like receptor 9 signaling activates NF-kappaB through IFN regulatory factor-8/IFN consensus sequence binding protein in dendritic cells. J Immunol 2004; 172: 6820-6827.
32. Appel S, Bringmann A, Grünebach F, Weck MM, Bauer J, Brossart P. Epithelial-specific transcription factor ESE-3 is involved in the development of monocyte-derived DCs. Blood 2006; 107: 3265-3270.
33. Tugores A, Le J, Sorokina I, Snijders AJ, Duyao M, Reddy PS et al. The epithelium-specific ETS protein EHF/ESE-3 is a contextdependent transcriptional repressor downstream of MAPK signaling cascades. J Biol Chem 2001; 276: 20397-20406.
34. Chung JS, Sato K, Dougherty II, Cruz Jr PD, Ariizumi K. DC-HIL is a negative regulator of T lymphocyte activation. Blood 2007; 109 4320-4327.
35. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18 767-811.
36. Chapuis F, Rosenzwajg M, Yagello M, Ekman M, Biberfeld P, Gluckman JC. Differentiation of human dendritic cells from monocytes in vitro. Eur J Immunol 1997; 27: 431-441.
37. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997; 9: 10-16.
38. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-376.
39. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987-995.
40. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499-511.
41. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170: 2081-2095.
42. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146: 3444-3451.
43. Buelens C, Verhasselt V, De Groote D, Thielemans K, Goldman M, Willems F. Human dendritic cell responses to lipopolysaccharide and CD40 ligation are differentially regulated by interleukin-10. Eur J Immunol 1997; 27: 1848-1852.
44. Corinti S, Albanesi C, la Sala A, Pastore S, Girolomoni G. Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol 2001; 166: 4312-4318.
45. De Smedt T, Van Mechelen M, De Becker G, Urbain J, Leo O, Moser M. Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol 1997; 27: 1229-1235.
46. O'Sullivan BJ, Thomas R. CD40 ligation conditions dendritic cell antigen-presenting function through sustained activation of NFkappaB. J Immunol 2002; 168: 5491-5498.
47. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993; 151: 1224-1234.
48. Willems F, Marchant A, Delville JP, Gerard C, Delvaux A, Velu T et al. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol 1994; 24: 1007-1009.
49. Denys A, Udalova IA, Smith C,Williams LM, Ciesielski CJ, Campbell J et al. Evidence for a dual mechanism for IL-10 suppression of TNF-alpha production that does not involve inhibition of p38 mitogen-activated protein kinase or NF-kappa B in primary human macrophages. J Immunol 2002; 168: 4837-4845.
50. Berlato C, Cassatella MA, Kinjyo I, Gatto L, Yoshimura A, Bazzoni F. Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharideinduced macrophage activation. J Immunol 2002; 168: 6404-6411.
51. Geijtenbeek TB, Van Vliet SJ, Koppel EA, Sanchez-Hernandez M, Vandenbroucke-Grauls CM, Appelmelk B et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp Med 2003; 197: 7-17.
52. Schottelius AJ, Mayo MW, Sartor RB, Baldwin Jr AS. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 1999; 274: 31868-31874.
53. Shames BD, Selzman CH, Meldrum DR, Pulido EJ, Barton HA, Meng X et al. Interleukin-10 stabilizes inhibitory kappaB-alpha in human monocytes. Shock 1998; 10: 389-394.
54. Zhou L, Nazarian AA, Smale ST. Interleukin-10 inhibits interleukin- 12 p40 gene transcription by targeting a late event in the activation pathway. Mol Cell Biol 2004; 24: 2385-2396.